OBJECTIVE
The study of the involvement of GWAS-significant (GWAS — Genome-Wide Association Study) is a genome—wide study of the links between single-nucleotide polymorphisms and human diseases; a method for identifying genetic variants associated with detectable traits or diseases by comparing the genomes of a large number of people, polymorphic loci associated with the level of sex hormone binding globulin (SHBG), in the development of genital endometriosis combined with uterine fibroids and endometrial hyperplasia.
MATERIAL AND METHODS
A comparative genetic analysis was performed on a sample of 98 patients with genital endometriosis combined with uterine fibroids and endometrial hyperplasia and 103 patients with isolated genital endometriosis (comparison group). Molecular genetic testing of four GWAS-significant polymorphic loci associated with SHBG levels (rs12150660 SHBG, rs1749332 PRMT6, rs3779195 BAIAP2L1, rs4149056 SLCO1B1) was performed. The associations of these polymorphisms with the risk of developing genital endometriosis in combination with uterine fibroids and endometrial hyperplasia, as well as the functional effects of SNPs (single nucleotide polymorphisms), were evaluated using the online resources HaploReg and Gtex Portal.
RESULTS
Allele variant A rs3779195 BAIAP2L1 increases the risk of developing genital endometriosis in combination with uterine fibroids and endometrial hyperplasia (odds ratio 2.09-2.85). The rs3779195 polymorphic locus of BAIAP2L1 determines the character of DNA interaction with the Foxp1 transcription factor, is associated with the transcription level of 5 genes (BAIAP2L1, BRI3, LMTK2, RP11-307C18.1, TECPR1), affects the splicing (excision of RNA regions) of 2 genes (BAIAP2L1, BRI3) in various organs and tissues, pathogenetically significant for endometriosis and other proliferative diseases of the uterus.
CONCLUSION
Polymorphic locus rs3779195 of the BAIAP2L1 gene is associated with the risk of developing genital endometriosis in combination with uterine fibroids and endometrial hyperplasia.